NVO
Novo Nordisk A/SHealthcareDrug Manufacturers - GeneralIncome
$46.55 · 15min delay
β 0.35A high-quality mega-cap income stock trading at a premium valuation. Frameworks sharply disagree on it.
52-wk low $35.1252-wk high $81.44
Mkt Cap
$206.35B
P/E
—
PEG
3.37
P/B
6.49
Dividend
3.88%
ROE
71.4%
About the business
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Who would buy NVO?
Consensus 32/100 · Polarized · Investors strongly disagree — this is where Prism is most useful.
2 8 5
Endorses
· 2 frameworks- Joel Greenblatt· Magic Formula100/100
ROE > 20% 71.4% clears "> 20.0%".
- Dividend Growth School· Dividend Income88/100
Dividend Yield > 2% 3.9% clears "> 2.0%".
Rejects
· 3 frameworksInsider activity · Sparse
No recent insider transactions
Strength 10/100
No Form 4 filings in the last 6 months. Insider inactivity is itself weak evidence — it usually reflects blackout windows or compensation cycles rather than a view on the stock.
- Sparse data — read with caution
No transactions match the selected filters.
Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 0.0% of shares outstanding.
Net 6M: +0 sh
Price history
—
Loading…
Drag across the chart to select a custom period — all analysis below refocuses to that window.
What this means: A notable drawdown — worth re-reading the framework verdicts below with the cheaper price in mind.
What would NVO do to your portfolio?
Add Novo Nordisk A/S at a hypothetical weight and Prism recalculates your whole book:
Risk metrics
Sharpe, Sortino, volatility, max drawdown, beta — before and after.
Sector concentration
How much this shifts your top sector weight and overall diversification.
Archetype tilt
Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.
NVO is currently tagged:IncomeWeak match (32/100)
Portfolio analytics are part of the member experience.
Sign in to run this simulationProbabilistic recommendation· rec-v1.0.0-2026-04
Novo Nordisk A/S · NVO
NVO: 52% estimated probability of outperforming over the next 12M window. 2 of 6 signal families positive (low confidence). Strongest support: 63% below fair value. Main risk to monitor: Reported earnings are not turning into cash.
Outperform prob.
52%
vs S&P 500 · 12M
Expected return
+1.1% → +25.1%
mid +13.1% / yr
Downside (p20)
-11.2%
stress -22.4%
Data quality
98/100
Excellent
Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.
Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.
Prism Score
Composite 64/100. Strongest contribution from quality; weakest from valuation. Risk patterns shaved 6 points off the composite.
Composite
64
/ 100
Deep valueval.
19/ 100
P/B 6.49× · FCF yield -5.8%
Margin of safetyval.
100/ 100
63% below fair value
Bull · base · bear scenarios
Three plausible paths over a 5-year horizon.
Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.
Bull
~25%$165.16
+28.8% / yr (5y)
Operating leverage kicks in or a new product line scales — margins inflect higher, growth steps up by 200–400 bps, and the multiple re-rates as the durability becomes obvious to a wider audience.
Drivers
- • Margin expands by 200–400 bps from 62%
- • Top-line accelerates 300–500 bps above current
- • Multiple re-rates one full turn higher
Base
~55%$127.05
+22.2% / yr (5y)
Business continues to compound at recent rates — 62% operating margin holds, 24% top-line growth persists, capital allocation stays disciplined. Multiple stays roughly where it is.
Global value comparison
Novo Nordisk A/S vs sector medians — GCC, MENA, and Global ex-US.
Sector: Healthcare. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.
| Metric | NVO | GCC median | MENA median | Global ex-US |
|---|---|---|---|---|
| P/E (TTM) | — | 24.0× | — | 20.0× |
| P/B | 6.49× | 4.80× | — | 3.80× |
| Dividend yield | 3.88% | 1.40% | — | 1.80% |
| ROE | 71.4% |
Earnings reaction explainer
NVO blew past estimates by 27.8%.
Reported EPS $6.63 vs $5.19 expected — well outside the normal beat-and-raise band. The market typically rewards a print this size only if it is read as durable, not one-off. Trailing operating margin: 61.6%.
- Growth investorsPositive
Confirms operating leverage — 67% trailing EPS growth + a beat of this size is the pattern that drives multi-year re-rates.
- Quality investorsPositive
If ROE (71%) and operating margin (62%) are stable or rising, the beat is consistent with compounding rather than one-off.
- Value investorsNeutral
A blow-out can pull future quarters forward — value investors will look for sustained margin, not a single-quarter spike.
News & events
Next earnings
Wed, Aug 5 · consensus EPS $5.19 · last actual $6.63
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Zacks · just now
Novo Nordisk (NVO) Reports Strong Weight-Loss Results for Higher-Dose Wegovy
InvestorsHub · just now
Novo Nordisk Says Higher-Dose Wegovy Shows Notable Weight Loss in New Data -- Shares Up Pre-Bell
MT Newswires · just now
Key Metrics at a Glance
P/E Ratio (TTM)
N/A
PEG Ratio
3.37
P/B Ratio
6.49
EPS Growth
67.1%
Revenue Growth
24.0%
Debt / Equity
0.72
Net Cash / Share
$-37.15
Return on Equity
71.4%
Gross Margin
83.2%
Operating Margin
61.6%
FCF / Share
$-3.59
Current Ratio
0.79